<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849000</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1209-301</org_study_id>
    <nct_id>NCT04849000</nct_id>
  </id_info>
  <brief_title>Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage</brief_title>
  <official_title>Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed Hyperlipemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with&#xD;
      hypercholesterolemia and hyperlipemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">June 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1209 monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-weeks or 16weeks Percentage change in LDL-C relative to baseline</measure>
    <time_frame>12-weeks or 16weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-weeks or 16weeks change in LDL-C relative to baseline；</measure>
    <time_frame>12-weeks or 16weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of changes in non-HDL-C, ApoB, TC/HDL-C, ApoB/ApoA1, LP (a) and TG relative to baseline and relative to baseline after 12 weeks or 16 weeks of treatment</measure>
    <time_frame>12 weeks or 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Hyperlipemia</condition>
  <arm_group>
    <arm_group_label>SHR-1209</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1209 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209</intervention_name>
    <description>SHR-1209</description>
    <arm_group_label>SHR-1209</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209 Placebo</intervention_name>
    <description>SHR-1209 Placebo</description>
    <arm_group_label>SHR-1209 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤80 on the date of signing the informed consent, male or female;&#xD;
&#xD;
          2. Fasting LDL-C was ≥2.6mmol/L and &lt;4.9mmol/L at screening and randomization；&#xD;
&#xD;
          3. Those who understand the study procedures and methods, volunteer to participate in the&#xD;
             study, and sign the informed consent in person.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have the following diseases or treatment history :(1) Have known allergic reaction to&#xD;
             experimental drugs, or have severe allergic reaction to other antibody drugs;(2)&#xD;
             previous diagnosis of cardiac function as defined by the New York Heart Association&#xD;
             (NYHA) grade III-IV;&#xD;
&#xD;
          2. Any of the laboratory indicators met the following criteria at screening or at random&#xD;
             :(1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 2&#xD;
             times the upper limit of normal (ULN), or total bilirubin exceeding 1.5 times the&#xD;
             upper limit of normal (ULN);(2) Creatine kinase (CK) exceeds 3 times the upper limit&#xD;
             of normal value (ULN);&#xD;
&#xD;
          3. General conditions :(1) the investigator judged that subcutaneous injection was not&#xD;
             appropriate;(2) Fertile female subjects who did not use contraception within 4 weeks&#xD;
             before screening;Or male or female subjects who do not agree to use high-efficiency&#xD;
             contraceptives during the trial and for 24 weeks after the last dosing;(3) Women who&#xD;
             are pregnant or lactating.&#xD;
&#xD;
          4. The Investigator determines that the subjects have poor compliance or have any factors&#xD;
             that may prevent them from participating in the study, including, but not limited to,&#xD;
             the study placing the subjects at unacceptable risk or possibly interfering with the&#xD;
             study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lijun Tang</last_name>
    <phone>+86 18570616501</phone>
    <email>lijun.tang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chanjuan Deng</last_name>
    <phone>+86 18672104055</phone>
    <email>chanjuan.deng@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Li Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

